Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm Fitchett DH; Borgundvaag B; Cantor W; Cohen E; Dhingra S; Fremes S; Gupta M; Heffernan M; Kertland H; Husain M; Langer A; Letovsky E; Goodman SGCan J Cardiol 2006[Jun]; 22 (8): 663-77Non-ST segment elevation acute coronary syndromes (NSTE ACS) include a clinical spectrum that ranges from unstable angina to NSTE myocardial infarction. Management goals aim to prevent recurrent ACS and improve long-term outcomes by choosing a treatment strategy according to an estimate of the risk of an adverse outcome. Recent registry data suggest that patients with NSTE ACS frequently do not receive recommended treatment, and that risk stratification is not used to determine either the choice of treatment or the speed of access to coronary angiography. The present article evaluates the evidence for recommended treatment using information from recent trials and guidelines published by the major cardiac organizations in Europe and North America. Using this information, a multidisciplinary group developed a simplified algorithm that uses risk stratification to select an optimal early management strategy. Long-term outcomes are improved by a multi-faceted vascular protection strategy that is initiated at the time of hospitalization for NSTE ACS.|*Algorithms[MESH]|*Electrocardiography[MESH]|Acute Disease[MESH]|Coronary Disease/diagnosis/*drug therapy/physiopathology[MESH]|Diagnosis, Differential[MESH]|Fibrinolytic Agents/*therapeutic use[MESH]|Humans[MESH]|Platelet Aggregation Inhibitors/*therapeutic use[MESH]|Practice Guidelines as Topic[MESH]|Prognosis[MESH]|Risk Factors[MESH] |
